Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
A look at the U.S. Food and Drug Administration’s drug approval review calendar.
The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Pregnant women are no more likely to become severely ill with COVID-19 than other women, according to a preliminary study in Britain, but most expectant mothers who do develop serious illness tend to be in the later stages of pregnancy.
Amphora has the opportunity to completely disrupt the birth control market with a new viscous and bioadhesive contraceptive.
The U.S. Food and Drug Administration approved South African drugmaker Aspen Pharmacare’s hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women.